摘要
目的探讨瑞格列奈(孚来迪)对2型糖尿病血糖和胰岛素分泌的影响。方法采用口服葡萄糖耐量试验(OGTT)和胰岛素释放试验新诊断的46例2型糖尿病患者,随机分为两组,23例为A组,口服孚来迪1mg/次,3次/日,于三餐进餐前服用。23例B组,口服格列齐特80mg/次,2次/日,于早晚餐进餐前服用。治疗5周后比较两组间血糖和胰岛素分泌的变化。结果口服孚来迪治疗后,血糖特别是餐后血糖得到明显控制,胰岛素早期分泌相基本恢复。与格列齐特相比对早期分泌时相的恢复效果显著。结论孚来迪是一种效果显著的2型糖尿病降糖药,副作用小,适用于早期诊断的2型糖尿病患者。
Aim To discuss the effect of repaglinide on the plasma glucose and insulin secretion of 2-type diabetes patients, Method Through the oral glucose tolerance test （OGTT） and insulin liberation test, the 26 type 2 diabetes patients newly diagnosed were taken orally repaglinide.After five weeks the changes on their plasma glucose and insulinism were observed carefully. Result After the oral taking of Repaglinide, the plasma glucose, especially for the postprandial plasma glucose, can be controlled obviously and the early secretory phase of insulin was recovered well elementarily. Conclusion Repaglinide is the antidiabetic with obvious effect for 2 type diabetes patients.
出处
《安徽医药》
CAS
2005年第10期734-735,共2页
Anhui Medical and Pharmaceutical Journal
